|
Patent 6,020,146 (1973 words) |
 | fibroblast cells to said suspected carcinogen, agglomerating the treated cells; incubating the agglomerated cells with a deoxyuridine analog; labeling the cells which have incorporated the deoxyuridine analog with an antibody to the deoxyuridine analog; and quantitating the amount of cells incorporating the deoxyuridine analog. |
| By deoxyuridine analog is meant a derivative of a deoxyuridine, which is incorporated by a cell transformed by a carcinogen but not incorporated by untransformed spheroid cells. |
| (c) administrating a deoxyuridine analog and a thymidilate synthetase inhibitor to said agglomerated cell sample, wherein said deoxyuridine analog is a halogenated deoxyuridine which is incorporated by cells transformed by a carcinogen and is not incorporated byuntransformed spheroid cells; |
| Anti-herpes simplex virus activity of 5-alkoxymethyl-2'-deoxycytidimes and their 5-monophosphates - Patent 4990499 (7556 words) |
| In contrast, deoxyuridine analogues are rapidly catabolized to pyrimidine bases by thymidine phosphorylase (Veres et al., 1986). |
| The cytotoxicity of deoxyuridine analogues is due to inhibition of thymidylate synthase by their corresponding monophosphates (DeClercq et al., 1982). |
| Penetration of MMdCyd in the CNS should be greater than its corresponding deoxyuridine derivative, 5-methoxymethyl-2'-deoxyuridine, because of its greater lipid solubility. |
Feeds |
Contact